221 related articles for article (PubMed ID: 31757943)
1. Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance.
Sun F; Li L; Yan P; Zhou J; Shapiro SD; Xiao G; Qu Z
Nat Commun; 2019 Nov; 10(1):5324. PubMed ID: 31757943
[TBL] [Abstract][Full Text] [Related]
2. Oncovirus Kaposi sarcoma herpesvirus (KSHV) represses tumor suppressor PDLIM2 to persistently activate nuclear factor κB (NF-κB) and STAT3 transcription factors for tumorigenesis and tumor maintenance.
Sun F; Xiao Y; Qu Z
J Biol Chem; 2015 Mar; 290(12):7362-8. PubMed ID: 25681443
[TBL] [Abstract][Full Text] [Related]
3. PDLIM2: Signaling pathways and functions in cancer suppression and host immunity.
Guo ZS; Qu Z
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188630. PubMed ID: 34571051
[TBL] [Abstract][Full Text] [Related]
4. PDLIM2 acts as a cancer suppressor gene in non-small cell lung cancer via the down regulation of NF-κB signaling.
Shi H; Ji Y; Li W; Zhong Y; Ming Z
Mol Cell Probes; 2020 Oct; 53():101628. PubMed ID: 32621848
[TBL] [Abstract][Full Text] [Related]
5. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
6. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8
Peng DH; Rodriguez BL; Diao L; Chen L; Wang J; Byers LA; Wei Y; Chapman HA; Yamauchi M; Behrens C; Raso G; Soto LMS; Cuentes ERP; Wistuba II; Kurie JM; Gibbons DL
Nat Commun; 2020 Sep; 11(1):4520. PubMed ID: 32908154
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.
Qu Z; Fu J; Yan P; Hu J; Cheng SY; Xiao G
J Biol Chem; 2010 Apr; 285(16):11786-92. PubMed ID: 20185823
[TBL] [Abstract][Full Text] [Related]
8. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
9. Tumor promoting effect of PDLIM2 downregulation involves mitochondrial ROS, oncometabolite accumulations and HIF-1α activation.
Yang JX; Chuang YC; Tseng JC; Liu YL; Lai CY; Lee AY; Huang CF; Hong YR; Chuang TH
J Exp Clin Cancer Res; 2024 Jun; 43(1):169. PubMed ID: 38880883
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.
Zhao L; Yu C; Zhou S; Lau WB; Lau B; Luo Z; Lin Q; Yang H; Xuan Y; Yi T; Zhao X; Wei Y
Oncotarget; 2016 Jan; 7(2):1408-20. PubMed ID: 26593252
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
12. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
13. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.
Wurster KD; Hummel F; Richter J; Giefing M; Hartmann S; Hansmann ML; Kreher S; Köchert K; Krappmann D; Klapper W; Hummel M; Wenzel SS; Lenz G; Janz M; Dörken B; Siebert R; Mathas S
Leukemia; 2017 Mar; 31(3):602-613. PubMed ID: 27538486
[TBL] [Abstract][Full Text] [Related]
15. [PDLIM2 and Its Role in Oncogenesis--Tumor Suppressor or Oncoprote?].
Maryáš J; Bouchal P
Klin Onkol; 2015; 28 Suppl 2():2S40-6. PubMed ID: 26374157
[TBL] [Abstract][Full Text] [Related]
16.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
19. PDLIM2 inhibits T helper 17 cell development and granulomatous inflammation through degradation of STAT3.
Tanaka T; Yamamoto Y; Muromoto R; Ikeda O; Sekine Y; Grusby MJ; Kaisho T; Matsuda T
Sci Signal; 2011 Dec; 4(202):ra85. PubMed ID: 22155789
[TBL] [Abstract][Full Text] [Related]
20. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
